Cargando…
Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dos...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524190/ https://www.ncbi.nlm.nih.gov/pubmed/31110537 http://dx.doi.org/10.5114/aoms.2018.76141 |
_version_ | 1783419504960733184 |
---|---|
author | Li, Kun-Peng Jin, Jing-Yu Yang, Jin-Shui Li, Yan Zhao, Wei Luo, Gui Zhu, Jian Zhang, Jiang-Lin Huang, Feng |
author_facet | Li, Kun-Peng Jin, Jing-Yu Yang, Jin-Shui Li, Yan Zhao, Wei Luo, Gui Zhu, Jian Zhang, Jiang-Lin Huang, Feng |
author_sort | Li, Kun-Peng |
collection | PubMed |
description | INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dose (YSP50), half dose (YSP25), and discontinuation (YSP0). Patients were assessed by the same rheumatologist every 8 weeks for 48 weeks. The primary endpoint was the proportion of non-failure patients in each group. If a flare occurred during the study period, the patient resumed YSP 50 mg QW or was switched to another tumor necrosis factor inhibitor. RESULTS: A total of 144 patients were included and each group included 48 patients. The proportion of non-failure patients was significantly greater in the YSP50 group than in the YSP0 group at 48 weeks (91.7% vs. 72.9%, p = 0.032). The difference in the other two comparisons was not statistically significant (YSP50 vs. YSP25 group, p = 0.522; YSP25 vs. YSP0 group, p = 0.132). The median time to flare did not differ significantly between the three groups (p > 0.05). Most patients who flared regained remission rapidly after resuming YSP 50 mg QW or starting adalimumab 40 mg every other week. CONCLUSIONS: For patients with early axSpA in remission on YSP for more than 12 weeks, continuation of YSP at full dose was superior to discontinuation of YSP, but not superior to halving the dose. |
format | Online Article Text |
id | pubmed-6524190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-65241902019-05-20 Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China Li, Kun-Peng Jin, Jing-Yu Yang, Jin-Shui Li, Yan Zhao, Wei Luo, Gui Zhu, Jian Zhang, Jiang-Lin Huang, Feng Arch Med Sci Clinical Research INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dose (YSP50), half dose (YSP25), and discontinuation (YSP0). Patients were assessed by the same rheumatologist every 8 weeks for 48 weeks. The primary endpoint was the proportion of non-failure patients in each group. If a flare occurred during the study period, the patient resumed YSP 50 mg QW or was switched to another tumor necrosis factor inhibitor. RESULTS: A total of 144 patients were included and each group included 48 patients. The proportion of non-failure patients was significantly greater in the YSP50 group than in the YSP0 group at 48 weeks (91.7% vs. 72.9%, p = 0.032). The difference in the other two comparisons was not statistically significant (YSP50 vs. YSP25 group, p = 0.522; YSP25 vs. YSP0 group, p = 0.132). The median time to flare did not differ significantly between the three groups (p > 0.05). Most patients who flared regained remission rapidly after resuming YSP 50 mg QW or starting adalimumab 40 mg every other week. CONCLUSIONS: For patients with early axSpA in remission on YSP for more than 12 weeks, continuation of YSP at full dose was superior to discontinuation of YSP, but not superior to halving the dose. Termedia Publishing House 2018-06-01 2019-05 /pmc/articles/PMC6524190/ /pubmed/31110537 http://dx.doi.org/10.5114/aoms.2018.76141 Text en Copyright: © 2018 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Clinical Research Li, Kun-Peng Jin, Jing-Yu Yang, Jin-Shui Li, Yan Zhao, Wei Luo, Gui Zhu, Jian Zhang, Jiang-Lin Huang, Feng Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China |
title | Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China |
title_full | Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China |
title_fullStr | Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China |
title_full_unstemmed | Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China |
title_short | Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China |
title_sort | full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in china |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524190/ https://www.ncbi.nlm.nih.gov/pubmed/31110537 http://dx.doi.org/10.5114/aoms.2018.76141 |
work_keys_str_mv | AT likunpeng fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT jinjingyu fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT yangjinshui fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT liyan fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT zhaowei fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT luogui fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT zhujian fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT zhangjianglin fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina AT huangfeng fulldosehalfdoseordiscontinuationofetanerceptbiosimilarinearlyaxialspondyloarthritispatientsarealworldstudyinchina |